Sambucus ebulus for COVID-19

c19early.org

COVID-19 Treatment Clinical Evidence

COVID-19 involves the interplay of 400+ viral and host proteins and factors, providing many therapeutic targets. c19early analyzes 6,000+ studies for 210+ treatments—over 17 million hours of research. Only three high-profit early treatments are approved in the US. In reality, many treatments reduce risk, with 25 low-cost treatments approved across 163 countries.

Naso/oropharyngeal treatment Effective Treatment directly to the primary source of initial infection.
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.

Sambucus ebulus may be beneficial for COVID-19 according to the study below. COVID-19 involves the interplay of 400+ viral and host proteins and factors providing many therapeutic targets. Scientists have proposed 11,000+ potential treatments. c19early.org analyzes 210+ treatments. We have not reviewed Sambucus ebulus in detail.

Study suggesting benefit with Sambucus ebulus

Cherneva et al., Traditional Use of Medicinal Plants for Symptom Relief During the COVID-19 Pandemic in Bulgaria, Plants, doi:10.3390/plants14233692

The COVID-19 pandemic has renewed global interest in medicinal plants as accessible sources of prophylactic and supportive therapies. Ethnobotanical research provides an important foundation for developing plant-based medicines with preventive and therapeutic potential. This study aimed (1) to investigate the distribution and indications for the use of medicinal plants in the prevention and relief of COVID-19-related symptoms among the Bulgarian population, and (2) to identify culturally significant species with potential for further development as antiviral agents. A total of 513 respondents from different regions and demographic groups in Bulgaria were interviewed. Their knowledge regarding the use of medicinal plants for COVID-19 prevention or treatment was quantitatively assessed using ethnobotanical indices: relative frequency of citation (RFC), informant consensus factor (FIC), fidelity level (FL), and use value (UV). Participants reported 45 species belonging to 43 genera and 23 families. The highest RFC and UVs were recorded for Matricaria chamomilla L., Tilia sp., Thymus vulgaris L., Zingiber officinale Roscoe, Mentha sp., Citrus x limon (L.) Osbeck, Rosa canina L., and Sideritis scardica Griseb. Culturally significant species identified were Thymus vulgaris L., Matricaria chamomilla L., Tilia sp., Mentha sp., Sideritis scardica Griseb, Zingiber officinale Roscoe, and Citrus x limon (L.) Osbeck. This ethnobotanical survey in Bulgaria documents culturally important medicinal plants that may have potential applications in prophylaxis and complementary therapy for COVID-19.